After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The company’s AN9025 will shortly enter phase 1.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
